Treatment-resistant depression affects a large proportion of people with major depressive disorder, and while ketamine offers rapid relief, its antidepressant effects fade within a few weeks. Now, researchers from Japan have identified the enzyme NOX-1 as a key molecular target to prolong ketamine’s antidepressant effects.
This article was originally published on MedicalXpress.com

